Trimethoprim susceptibility in E. coli community-acquired urinary tract infections in France |
| |
| Authors: | C. Duployez J. Robert A. Vachée |
| |
| Affiliation: | 1. Laboratoire de microbiologie, centre hospitalier Roubaix, 59100 Roubaix, France;2. Conseil scientifique de l’observatoire national de l’épidémiologie de la résistance bactérienne aux antibiotiques, 75006 Paris, France;3. Inserm, U1135, centre d’immunologie et des maladies infectieuses, CIMI, Team E13 (Bactériologie), Sorbonne Universités, UPMC université Paris 06, CR7, 75005 Paris, France;4. Bactériologie-hygiène, hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, AP–HP, 75013 Paris, France |
| |
| Abstract: | ObjectivesTrimethoprim has been recently included in the French guidelines for the treatment of urinary tract infections, but no epidemiological data supports its use. We aimed to determine the trimethoprim susceptibility of Escherichia coli isolates responsible for community-acquired urinary tract infections in women of childbearing age.Materials and methodsWe conducted a national prospective survey. A total of 350 strains of E. coli isolated from urines in 35 laboratories were included. Antibiotic susceptibility testing was performed in each laboratory.ResultsWe reported a susceptibility rate of 78%, and a similar clinical categorization between trimethoprim and cotrimoxazole for 97.4% of isolates. We pointed out an association between resistance to trimethoprim and other antibiotic classes.ConclusionThe results support trimethoprim as a second-line therapy based on antibiotic susceptibility testing results. We confirm that trimethoprim and cotrimoxazole susceptibility rates are very close. |
| |
| Keywords: | Trimethoprim Urinary tract infections Infections urinaires Triméthoprime |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
